Potential of Oncostatin M to accelerate diabetic wound healing

Soo Hye Shin, Seung-Kyu Han, Seong-Ho Jeong, Woo-Kyung Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Oncostatin M (OSM) is a multifunctional cytokine found in a variety of pathologic conditions, which leads to excessive collagen deposition. Current studies demonstrate that OSM is also a mitogen for fibroblasts and has an anti-inflammatory action. It was therefore hypothesised that OSM may play an important role in healing of chronic wounds that usually involve decreased fibroblast function and persist in the inflammatory stage for a long time. In a previous in vitro study, the authors showed that OSM increased wound healing activities of diabetic dermal fibroblasts. However, wound healing in vivo is a complex process involving multiple factors. Thus, the purpose of this study was to evaluate the effect of OSM on diabetic wound healing in vivo. Five diabetic mice were used in this study. Four full-thickness round wounds were created on the back of each mouse (total 20 wounds). OSM was applied on the two left-side wounds (n = 10) and phosphate-buffered saline was applied on the two right-side wounds (n = 10). After 10 days, unhealed wound areas of the OSM and control groups were compared using the stereoimage optical topometer system. Also, epithelialisation, wound contraction and reduction in wound volume in each group were compared. The OSM-treated group showed superior results in all of the tested parameters. In particular, the unhealed wound area and the reduction in wound volume demonstrated statistically significant differences (P < 0·05). The results of this study indicate that topical application of OSM may have the potential to accelerate healing of diabetic wounds.

Original languageEnglish
Pages (from-to)398-403
Number of pages6
JournalInternational Wound Journal
Volume11
Issue number4
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Oncostatin M
Wound Healing
Wounds and Injuries
Fibroblasts
Re-Epithelialization
Optical Devices
Mitogens
Anti-Inflammatory Agents
Collagen
Phosphates
Cytokines

Keywords

  • Diabetic wound
  • Oncostatin M
  • Wound healing

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Potential of Oncostatin M to accelerate diabetic wound healing. / Shin, Soo Hye; Han, Seung-Kyu; Jeong, Seong-Ho; Kim, Woo-Kyung.

In: International Wound Journal, Vol. 11, No. 4, 01.01.2014, p. 398-403.

Research output: Contribution to journalArticle

@article{6545a1b25d2045fbb1b5a0550f887462,
title = "Potential of Oncostatin M to accelerate diabetic wound healing",
abstract = "Oncostatin M (OSM) is a multifunctional cytokine found in a variety of pathologic conditions, which leads to excessive collagen deposition. Current studies demonstrate that OSM is also a mitogen for fibroblasts and has an anti-inflammatory action. It was therefore hypothesised that OSM may play an important role in healing of chronic wounds that usually involve decreased fibroblast function and persist in the inflammatory stage for a long time. In a previous in vitro study, the authors showed that OSM increased wound healing activities of diabetic dermal fibroblasts. However, wound healing in vivo is a complex process involving multiple factors. Thus, the purpose of this study was to evaluate the effect of OSM on diabetic wound healing in vivo. Five diabetic mice were used in this study. Four full-thickness round wounds were created on the back of each mouse (total 20 wounds). OSM was applied on the two left-side wounds (n = 10) and phosphate-buffered saline was applied on the two right-side wounds (n = 10). After 10 days, unhealed wound areas of the OSM and control groups were compared using the stereoimage optical topometer system. Also, epithelialisation, wound contraction and reduction in wound volume in each group were compared. The OSM-treated group showed superior results in all of the tested parameters. In particular, the unhealed wound area and the reduction in wound volume demonstrated statistically significant differences (P < 0·05). The results of this study indicate that topical application of OSM may have the potential to accelerate healing of diabetic wounds.",
keywords = "Diabetic wound, Oncostatin M, Wound healing",
author = "Shin, {Soo Hye} and Seung-Kyu Han and Seong-Ho Jeong and Woo-Kyung Kim",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/j.1742-481X.2012.01107.x",
language = "English",
volume = "11",
pages = "398--403",
journal = "International Wound Journal",
issn = "1742-4801",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Potential of Oncostatin M to accelerate diabetic wound healing

AU - Shin, Soo Hye

AU - Han, Seung-Kyu

AU - Jeong, Seong-Ho

AU - Kim, Woo-Kyung

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Oncostatin M (OSM) is a multifunctional cytokine found in a variety of pathologic conditions, which leads to excessive collagen deposition. Current studies demonstrate that OSM is also a mitogen for fibroblasts and has an anti-inflammatory action. It was therefore hypothesised that OSM may play an important role in healing of chronic wounds that usually involve decreased fibroblast function and persist in the inflammatory stage for a long time. In a previous in vitro study, the authors showed that OSM increased wound healing activities of diabetic dermal fibroblasts. However, wound healing in vivo is a complex process involving multiple factors. Thus, the purpose of this study was to evaluate the effect of OSM on diabetic wound healing in vivo. Five diabetic mice were used in this study. Four full-thickness round wounds were created on the back of each mouse (total 20 wounds). OSM was applied on the two left-side wounds (n = 10) and phosphate-buffered saline was applied on the two right-side wounds (n = 10). After 10 days, unhealed wound areas of the OSM and control groups were compared using the stereoimage optical topometer system. Also, epithelialisation, wound contraction and reduction in wound volume in each group were compared. The OSM-treated group showed superior results in all of the tested parameters. In particular, the unhealed wound area and the reduction in wound volume demonstrated statistically significant differences (P < 0·05). The results of this study indicate that topical application of OSM may have the potential to accelerate healing of diabetic wounds.

AB - Oncostatin M (OSM) is a multifunctional cytokine found in a variety of pathologic conditions, which leads to excessive collagen deposition. Current studies demonstrate that OSM is also a mitogen for fibroblasts and has an anti-inflammatory action. It was therefore hypothesised that OSM may play an important role in healing of chronic wounds that usually involve decreased fibroblast function and persist in the inflammatory stage for a long time. In a previous in vitro study, the authors showed that OSM increased wound healing activities of diabetic dermal fibroblasts. However, wound healing in vivo is a complex process involving multiple factors. Thus, the purpose of this study was to evaluate the effect of OSM on diabetic wound healing in vivo. Five diabetic mice were used in this study. Four full-thickness round wounds were created on the back of each mouse (total 20 wounds). OSM was applied on the two left-side wounds (n = 10) and phosphate-buffered saline was applied on the two right-side wounds (n = 10). After 10 days, unhealed wound areas of the OSM and control groups were compared using the stereoimage optical topometer system. Also, epithelialisation, wound contraction and reduction in wound volume in each group were compared. The OSM-treated group showed superior results in all of the tested parameters. In particular, the unhealed wound area and the reduction in wound volume demonstrated statistically significant differences (P < 0·05). The results of this study indicate that topical application of OSM may have the potential to accelerate healing of diabetic wounds.

KW - Diabetic wound

KW - Oncostatin M

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=84904402750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904402750&partnerID=8YFLogxK

U2 - 10.1111/j.1742-481X.2012.01107.x

DO - 10.1111/j.1742-481X.2012.01107.x

M3 - Article

VL - 11

SP - 398

EP - 403

JO - International Wound Journal

JF - International Wound Journal

SN - 1742-4801

IS - 4

ER -